Skip to main content Accessibility help
×
×
Home
  • Print publication year: 2010
  • Online publication date: December 2010

8 - Genetics and pain

from Section 1 - Pain Definitions
Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

The Essence of Analgesia and Analgesics
  • Online ISBN: 9780511841378
  • Book DOI: https://doi.org/10.1017/CBO9780511841378
Please enter your name
Please enter a valid email address
Who would you like to send this to *
×

References

1. KlepstadP, RakvågT, KaasaS. The 118A_G polymorphism in the human opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004;48:1232–1239.
2. BesslerH, ShavitY. Post-operative pain, morphine consumption, and genetic polymorphism of IL-1β and IL-1 receptor antagonist. Neurosci Lett 2006;404:154–158.
3. ChouWY, YangLC. Association of m-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006;50: 787–792.
4. CampaD et al. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83;559–566.
5. CandiottiK, YangZ. The impact of CYP2D6 genetic polymorphisms on post-operative morphine consumption. Pain Med 2009;10, No5.
6. RakvagTT, KlepstadP, BaarC, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005;116:73–89.
7. ZubietaJK, HeitzegMM, SmithYR. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003;299:1240–1243.
8. FosterA, MobleyE, WangZ. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Practice 2007;4:352–356.
9. ReynoldsK, Ramey-HartungB, JortaniS. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy. Clin Lab Med 2008;28:581–598.
10. ChevalierX. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005;32:7.
11. EdwardsR. Genetic predictors of acute and chronic pain. Curr Rheumatol Rep 2006; 8:411–417.
12. MogilJS, RitchieJ, SmithSB, et al. Melancortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet 2005;42:583–587.
13. StamerU. Genetic factors in pain and its treatmentCurr Opin Anaesthesiol 2007;20:478–484.
14. LÖtschJ, GeisslingerG, TegederI. Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther 2009;124:168–184.
15. FujitaK, AndoY, YamamotoW, et al. Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol 2010;65:251–258.
16. ComptonP, GeschwindD. Association between human m-opioid receptor gene polymorphism, pain tolerance, and opioid addiction. Am J Med Genet Part B (Neuropsychiatric Genetics) 2003;121B:76–82.
17. SomogyiA, BarrattD, CollerJ. Pharmacogenetics of Opioids. Clin Pharmacol Ther 2007;81:429–444.